Different effects of atrial and C-type natriuretic peptide on the urinary excretion of endothelin-1 in man

Clin Sci (Lond). 1998 Nov;95(5):595-602. doi: 10.1042/cs0950595.

Abstract

1. Following the observation that brain natriuretic peptide enhances the urinary excretion rate of endothelin-1, the relationship between natriuretic peptides and urinary endothelin-1 was further investigated. Six healthy volunteers received, on three different occasions, increasing doses of atrial or C-type natriuretic peptide (0, 2 and 4 pmol.min-1.kg-1 for 1 h each), or placebo.2. Atrial natriuretic peptide caused significant increases in the urinary excretion of cGMP, sodium and endothelin-1, without affecting plasma endothelin-1, renal plasma flow, glomerular filtration rate and urine flow rate. C-type natriuretic peptide did not modify any of these parameters. During atrial natriuretic peptide infusion, urinary endothelin-1 directly correlated with plasma atrial natriuretic peptide, urinary cGMP and sodium excretion.3. These results indicate that enhancement of the urinary excretion of endothelin-1 by natriuretic peptides is dose-dependent and somewhat related to their ability to bind to natriuretic peptide receptors A, activate guanylate cyclase and induce a natriuretic response.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Analysis of Variance
  • Atrial Natriuretic Factor / pharmacology*
  • Cross-Over Studies
  • Cyclic GMP / urine
  • Dose-Response Relationship, Drug
  • Endothelin-1 / urine*
  • Female
  • Humans
  • Male
  • Natriuresis
  • Natriuretic Peptide, Brain / pharmacology*
  • Single-Blind Method

Substances

  • Endothelin-1
  • Natriuretic Peptide, Brain
  • Atrial Natriuretic Factor
  • Cyclic GMP